^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    QTX3046

    i
    Company:
    Quanta Therap
    Drug class:
    KRAS G12D inhibitor
    Related drugs:
    Apply
    QTX3046 in Patients with KRAS G12D Mutations (NCT06428500)
    Phase 1
    Quanta Therapeutics
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    05/30/2024
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    KRAS
    |
    Erbitux (cetuximab) • QTX3046